Literature DB >> 14616406

The pharmacokinetics of voriconazole.

Atholl Johnston1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 14616406      PMCID： PMC1884313          DOI： 10.1046/j.1365-2125.2003.01991.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN： 0306-5251            Impact factor:   4.335


× No keyword cloud information.
  6 in total

1.  Comparative in-vitro activity of voriconazole (UK-109,496) and six other antifungal agents against clinical isolates of Scedosporium prolificans and Scedosporium apiospermum.

Authors:  M Cuenca-Estrella; B Ruiz-Díez; J V Martínez-Suárez; A Monzón; J L Rodríguez-Tudela
Journal:  J Antimicrob Chemother       Date:  1999-01       Impact factor: 5.790

2.  Voriconazole: A second-generation triazole.

Authors:  P. H. Chandrasekar; E. Manavathu
Journal:  Drugs Today (Barc)       Date:  2001-02       Impact factor: 2.245

3.  The disposition of voriconazole in mouse, rat, rabbit, guinea pig, dog, and human.

Authors:  S J Roffey; S Cole; P Comby; D Gibson; S G Jezequel; A N R Nedderman; D A Smith; D K Walker; N Wood
Journal:  Drug Metab Dispos       Date:  2003-06       Impact factor: 3.922

4.  Identification of the cytochrome P450 enzymes involved in the N-oxidation of voriconazole.

Authors:  R Hyland; B C Jones; D A Smith
Journal:  Drug Metab Dispos       Date:  2003-05       Impact factor: 3.922

Review 5.  Cytochrome P450 of fungi: primary target for azole antifungal agents.

Authors:  Y Yoshida
Journal:  Curr Top Med Mycol       Date:  1988

6.  Comparison of the in-vitro activity of voriconazole (UK-109,496), itraconazole and amphotericin B against clinical isolates of Aspergillus fumigatus.

Authors:  M Cuenca-Estrella; J L Rodríguez-Tudela; E Mellado; J V Martínez-Suárez; A Monzón
Journal:  J Antimicrob Chemother       Date:  1998-10       Impact factor: 5.790
  6 in total
  5 in total

1.  Therapeutic Drug Monitoring and Genotypic Screening in the Clinical Use of Voriconazole.

Authors:  Brad Moriyama; Sameer Kadri; Stacey A Henning; Robert L Danner; Thomas J Walsh; Scott R Penzak
Journal:  Curr Fungal Infect Rep       Date:  2015-04-16

2.  Real-time treatment guidelines: considerations during the Exserohilum rostratum outbreak in the United States.

Authors:  Peter G Pappas; Dimitrios P Kontoyiannis; John R Perfect; Tom M Chiller
Journal:  Antimicrob Agents Chemother       Date:  2013-02-05       Impact factor: 5.191

3.  Observational study of the clinical efficacy of voriconazole and its relationship to plasma concentrations in patients.

Authors:  Peter F Troke; Hans P Hockey; William W Hope
Journal:  Antimicrob Agents Chemother       Date:  2011-07-18       Impact factor: 5.191

Review 4.  Current concepts in antifungal pharmacology.

Authors:  Russell E Lewis
Journal:  Mayo Clin Proc       Date:  2011-08       Impact factor: 7.616

Review 5.  Conazoles.

Authors:  Jan Heeres; Lieven Meerpoel; Paul Lewi
Journal:  Molecules       Date:  2010-06-09       Impact factor: 4.411
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.